• 1
    Lennard-Jones JE, Longmore AJ, Newell AC, Wilson CWE, Avery Jones F. An assessment of prednisone, salazopyrin, and topical hydrocortisone hemisuccinate used as out-patient treatment for ulcerative colitis. Gut 1960; 1: 21722.
  • 2
    Baron JH, Connell AM, Lennard-Jones JE, Avery Jones F. Sulphasalazine and salicylazsulphadimidine in ulcerative colitis. Lancet 1962; i: 10946.
  • 3
    Dick AP, Grayson MJ, Carpenter RG, Petrie A. Controlled trial of sulphasalazine in the treatment of ulcerative colitis. Gut 1964; 5: 43742.
  • 4
    Sutherland LR, May GR, Shaffer EA. Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. Ann Intern Med 1993; 118: 5409.
  • 5
    Sutherland L, Roth D, Beck P, May G, Makiyama K. Oral 5-aminosalicylic acid for inducing remission in ulcerative colitis (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software, 2000.
  • 6
    Klotz U, Maier K, Fischer C, Heinkel K. Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn’s disease. N Engl J Med 1980; 303: 1499502.
  • 7
    Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet 1977; ii: 8925.
  • 8
    Van Hees PAM, Bakker JH, Van Tongeren JHM. Effect of sulphapyridine, 5-aminosalicylic acid, and placebo in patients with idiopathic proctitis: a study to determine the active therapeutic moiety of sulphasalazine. Gut 1980; 21: 6325.
  • 9
    Riley SA, Mani V, Goodman MJ, Herd ME, Dutt S, Turnberg LA. Comparison of delayed release 5-aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse. Gut 1988; 29: 66974.
  • 10
    Willoughby CP, Cowan RE, Gould SR, Machell RJ, Stewart JB. Double-blind comparison of olsalazine and sulphasalazine in active ulcerative colitis. Scand J Gastroenterol 1988; 23(Suppl. 148): 404.
  • 11
    Giaffer MH, O'Brien CJ, Holdsworth CD. Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine. Aliment Pharmacol Ther 1992; 6: 519.
  • 12
    Green JRB. The treatment of ulcerative colitis with balsalazide sodium. Inflammopharmacology 1993; 2: 28995.
  • 13
    Green JRB, Lobo AJ, Holdsworth CD, et al. Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. Gastroenterology 1998; 114: 1522.
  • 14
    Levine DS, Pruitt R, Riff D, et al. A multi-center, double-blind dose–response trial of Colazide (balsalazide disodium) and Asacol (mesalamine) for mild–moderately active ulcerative colitis. Gastroenterology 1997; 112: A1026A1026(Abstract).
  • 15
    Pruitt R, Hanson J, Safdi M, et al. Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute ulcerative colitis. Gastroenterology 2000; 118: A1201(Abstract).
  • 16
    McIntyre PB, Rodrigues CA, Lennard-Jones JE, et al. Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. Aliment Pharmacol Ther 1988; 2: 23743.
  • 17
    Green JRB, Gibson JA, Kerr GD, et al. Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. Aliment Pharmacol Ther 1998; 12: 120716.
  • 18
    Mansfield JC, Giaffer MH, Cann PA, Holdsworth CD, McKenna DM, Thornton PC. Is high dose balsalazide better than sulphasalazine in the initial management of ulcerative colitis? Gut 1991; 32: A1217A1217(Abstract).
  • 19
    Green JRB, Swan CHJ, Rowlinson AE, et al. Sulphasalazine or high dose balsalazide to treat acute relapse in ulcerative colitis? Results of a randomized trial. Gastroenterology 1993; 104: A709A709(Abstract).
  • 20
    Altman DG. Practical Statistics for Medical Research. London: Chapman & Hall, 1991.
  • 21
    Azad Khan AK, Howes DT, Piris J, Truelove SC. Optimum dose of sulphasalazine for the maintenance treatment in ulcerative colitis. Gut 1980; 21: 23240.
  • 22
    Rao SSC, Dundas SAC, Holdsworth CD, Cann PA, Palmer KR, Corbett CL. Olsalazine or sulphasalazine in first attacks of ulcerative colitis? A double blind study. Gut 1989; 30: 6759.
  • 23
    Hanauer S, Schwartz J, Robinson M, et al. Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Am J Gastroenterol 1993; 88: 118897.
  • 24
    Vecchi M, Meucci G, Gionchetti P, et al. Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. Aliment Pharmacol Ther 2001; 15: 2516.
  • 25
    Rudra T, Motley R, Rhodes J. Does smoking improve colitis? Scand J Gastroenterol 1989; 24: 613.
  • 26
    Pullan RD, Rhodes J, Ganesh S, et al. Transdermal nicotine for active ulcerative colitis. N Engl J Med 1994; 330: 8115.
  • 27
    Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. Br Med J 1989; 298: 826.
  • 28
    Truelove SC, Watkinson G, Draper G. Comparison of corticosteroid and sulphasalazine therapy in ulcerative colitis. Br Med J 1962; 2: 170811.